Association and Correlation of Different Chemotherapy Regimens and Doses with Incidence and Severity of Thrombocytopenia among Solid Cancer Patients

Z. M. Yusoff, Abdulrasool M. Wayyes, M. M. Hareeja, Saif S. Abbas
{"title":"Association and Correlation of Different Chemotherapy Regimens and Doses with Incidence and Severity of Thrombocytopenia among Solid Cancer Patients","authors":"Z. M. Yusoff, Abdulrasool M. Wayyes, M. M. Hareeja, Saif S. Abbas","doi":"10.54133/ajms.v1i.21","DOIUrl":null,"url":null,"abstract":"Background: Thrombocytopenia is an abnormal decrease in platelet numbers and is a major detrimental side effect of chemotherapy or of cancer itself. Thrombocytopenia can lead to hemorrhage in vital organs, which is particularly a problematic specifically in solid cancer patients, and has a substantial negative effect on cancer patients’ quality of life (QOL). Thrombocytopenia ranges from mild bleeding from small blood vessels to severe bleeding from large blood vessels. Objectives: The present study aimed to describe the effect of chemotherapy regimens and doses on thrombocytopenia incidence and severity among solid cancer patients with thrombocytopenia. Materials and Methods: This retrospective observational study was conducted in Penang Hospital, a government hospital on Penang island, and included 341 cancer patients with thrombocytopenia who were admitted between 2003 and 2009. The main statistical tests used were the Chi-square test and logistic regression. The level of significance was set at P < 0.05. Results: Of the 341 patients included, 21 (6.2%) had thrombocytopenia before chemotherapy and the remaining 320 (93.8%) developed it after chemotherapy. The majority of patients had moderate thrombocytopenia (n=172; 53.8%), followed by mild (n=97; 30.3%), and severe thrombocytopenia (n=51; 15.9%). FEC, 5-FU+5-FU, Docetaxel and Cisplatin regimen had strong associations and correlation with thrombocytopenia incidence and severity, but the associations and correlations for thrombocytopenia severity were stronger than those for incidence. The dosage of 5-FU, cyclophosphamide, docetaxel and cisplatin plays a critical role in thrombocytopenia incidence and severity. Conclusion: Monitoring and determination of hemoglobin levels for cancer patients treated with FEC, 5-FU+5-FU, Docetaxel, and Cisplatin specifically with high doses must be emphasized and a focus of particular attention.","PeriodicalId":433524,"journal":{"name":"Al-Rafidain Journal of Medical Sciences ( ISSN: 2789-3219 )","volume":"100 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Al-Rafidain Journal of Medical Sciences ( ISSN: 2789-3219 )","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.54133/ajms.v1i.21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Background: Thrombocytopenia is an abnormal decrease in platelet numbers and is a major detrimental side effect of chemotherapy or of cancer itself. Thrombocytopenia can lead to hemorrhage in vital organs, which is particularly a problematic specifically in solid cancer patients, and has a substantial negative effect on cancer patients’ quality of life (QOL). Thrombocytopenia ranges from mild bleeding from small blood vessels to severe bleeding from large blood vessels. Objectives: The present study aimed to describe the effect of chemotherapy regimens and doses on thrombocytopenia incidence and severity among solid cancer patients with thrombocytopenia. Materials and Methods: This retrospective observational study was conducted in Penang Hospital, a government hospital on Penang island, and included 341 cancer patients with thrombocytopenia who were admitted between 2003 and 2009. The main statistical tests used were the Chi-square test and logistic regression. The level of significance was set at P < 0.05. Results: Of the 341 patients included, 21 (6.2%) had thrombocytopenia before chemotherapy and the remaining 320 (93.8%) developed it after chemotherapy. The majority of patients had moderate thrombocytopenia (n=172; 53.8%), followed by mild (n=97; 30.3%), and severe thrombocytopenia (n=51; 15.9%). FEC, 5-FU+5-FU, Docetaxel and Cisplatin regimen had strong associations and correlation with thrombocytopenia incidence and severity, but the associations and correlations for thrombocytopenia severity were stronger than those for incidence. The dosage of 5-FU, cyclophosphamide, docetaxel and cisplatin plays a critical role in thrombocytopenia incidence and severity. Conclusion: Monitoring and determination of hemoglobin levels for cancer patients treated with FEC, 5-FU+5-FU, Docetaxel, and Cisplatin specifically with high doses must be emphasized and a focus of particular attention.
不同化疗方案和剂量与实体癌患者血小板减少发生率和严重程度的相关性
背景:血小板减少症是血小板数量的异常减少,是化疗或癌症本身的主要有害副作用。血小板减少可导致重要器官出血,这在实体癌患者中尤其成问题,并对癌症患者的生活质量(QOL)产生重大的负面影响。血小板减少症的范围从小血管的轻度出血到大血管的严重出血。目的:本研究旨在描述化疗方案和剂量对实体癌伴血小板减少患者血小板减少发生率和严重程度的影响。材料和方法:本回顾性观察性研究在槟城岛的政府医院Penang医院进行,纳入了2003年至2009年间入院的341例患有血小板减少症的癌症患者。使用的主要统计检验为卡方检验和逻辑回归。P < 0.05为显著性水平。结果:341例患者中,化疗前出现血小板减少21例(6.2%),化疗后出现血小板减少320例(93.8%)。大多数患者有中度血小板减少症(n=172;53.8%),其次为轻度(n=97;30.3%)和严重血小板减少症(n=51;15.9%)。FEC、5-FU+5-FU、多西他赛和顺铂方案与血小板减少发生率和严重程度有较强的关联和相关性,但血小板减少严重程度的关联和相关性强于发生率。5-FU、环磷酰胺、多西紫杉醇和顺铂的剂量对血小板减少的发生率和严重程度起关键作用。结论:对于接受FEC、5-FU+5-FU、多西他赛和顺铂治疗的癌症患者,特别是大剂量的患者,血红蛋白水平的监测和测定必须得到重视和特别关注。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信